Rayner's Recently Acquired Ophteis OVD Range and What This Means for Cataract Surgery

Professor Steve Arshinoff and Rayner CEO Tim Clover announce Rayner's recent acquisition of the Ophteis OVD range at the Company's celebratory event, held at the 2015 ESCRS in Barcelona.

Redirect to video article

 

Related Videos
Related Content

Verana Health unveils Qdata Anti-VEGF Market Tracker

March 28th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Ocugen announces FDA approval for enrollment of pediatric patients in ongoing OCU400 Phase 1/2 clinical trial

March 28th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Getting ophthalmic biosimilars to market continues to prove difficult

March 27th 2023

Study: Tiny nanoparticle could have big impact on patients receiving corneal transplants

March 27th 2023

Verana Health unveils Qdata Anti-VEGF Market Tracker

March 28th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Ocugen announces FDA approval for enrollment of pediatric patients in ongoing OCU400 Phase 1/2 clinical trial

March 28th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Getting ophthalmic biosimilars to market continues to prove difficult

March 27th 2023

Study: Tiny nanoparticle could have big impact on patients receiving corneal transplants

March 27th 2023

Verana Health unveils Qdata Anti-VEGF Market Tracker

March 28th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Ocugen announces FDA approval for enrollment of pediatric patients in ongoing OCU400 Phase 1/2 clinical trial

March 28th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Getting ophthalmic biosimilars to market continues to prove difficult

March 27th 2023

Study: Tiny nanoparticle could have big impact on patients receiving corneal transplants

March 27th 2023
© 2023 MJH Life Sciences

All rights reserved.